An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Sym 013 (Primary)
- Indications Cancer; Colorectal cancer; Glandular and epithelial neoplasms
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Symphogen
- 03 Feb 2022 Results published in the Investigational New Drugs
- 09 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.